Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on medication adherence

LIVE: Thursday 27th June 2024, 18:00-19:30 (CEST)
Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.
ADVANCED SEARCH
Log in
Top
Cancer Immunology, Immunotherapy
Published in: Cancer Immunology, Immunotherapy 2-3/1999

01-06-1999 | ORIGINAL ARTICLE

Differential lytic and agglutinating activity of the anti-Lewisx monoclonal antibody FC-2.15 on human polymorphonuclear neutrophils and MCF-7 breast tumor cells. In vitro and ex vivo studies

Authors: Mariana Capurro, Cecilia Ballaré, Laura Bover, Paula Portela, Jesé Mordoh

Published in: Cancer Immunology, Immunotherapy | Issue 2-3/1999

Login to get access
Metadata
Title
Differential lytic and agglutinating activity of the anti-Lewisx monoclonal antibody FC-2.15 on human polymorphonuclear neutrophils and MCF-7 breast tumor cells. In vitro and ex vivo studies
Authors
Mariana Capurro
Cecilia Ballaré
Laura Bover
Paula Portela
Jesé Mordoh
Publication date
01-06-1999
Publisher
Springer-Verlag
Published in
Cancer Immunology, Immunotherapy / Issue 2-3/1999
Print ISSN: 0340-7004
Electronic ISSN: 1432-0851
DOI
https://doi.org/10.1007/s002620050553

Other articles of this Issue 2-3/1999

Cancer Immunology, Immunotherapy 2-3/1999 Go to the issue

ORIGINAL ARTICLE

Treatment of medullary thyroid carcinoma by combined expression of suicide and interleukin-2 genes

ORIGINAL ARTICLE

Granulocyte/macrophage-colony-stimulating factor released by adenovirally transduced CT26 cells leads to the local expression of macrophage inflammatory protein 1α and accumulation of dendritic cells at vaccination sites in vivo

ORIGINAL ARTICLE

Increased generation of autologous tumor-reactive lymphocytes by anti-CD3 monoclonal antibody and prothymosin α

ORIGINAL ARTICLE

Homing of intravenously and intralymphatically injected human dendritic cells generated in vitro from CD34+ hematopoietic progenitor cells

ORIGINAL ARTICLE

Neuronal autoantibody titers in the course of small-cell lung carcinoma and platinum-associated neuropathy

ORGINAL ARTICLE

In vitro analysis of the melanoma/endothelium interaction increasing the release of soluble intercellular adhesion molecule 1 by endothelial cells
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine
Image Credits